The bill adds a new section to 38 U.S.C. creating "innovative therapies centers of excellence" within the Department of Veterans Affairs. It directs the Secretary, on the Under Secretary for Health's recommendation, to designate at least five VA medical facilities as centers, require academic affiliations and research capacity, and, subject to appropriations, operate the centers with dedicated funding and national coordination.
This matters for VA administrators, academic affiliates, clinicians, and companies developing psychedelic and other experimental therapies. The measure both authorizes $30 million annually for center research and education and creates structural requirements — peer review, training links with accredited schools, a national data repository, and annual reporting to Congress — that steer how the VA will integrate regulated but controversial therapies into veteran care.
At a Glance
What It Does
The bill requires the Secretary of Veterans Affairs to designate at least five VA medical facilities as innovative therapies centers of excellence, establish them (subject to appropriations), and run them as a coordinated national system with research, education, and clinical activities. It sets designation criteria, creates a specialized peer review panel to rank proposals, mandates annual reporting to Congress, and authorizes $30 million per year for research and education.
Who It Affects
Directly affects VA medical centers that seek designation, affiliated accredited medical schools and residency programs (including psychiatry and social work), VA researchers and clinicians working on the named therapies, and veterans seeking care for conditions listed as 'covered conditions.' It also impacts federal budgeting and offices that allocate VA medical services and research funds.
Why It Matters
The bill institutionalizes VA support for therapies that include controlled and experimental agents (e.g., psilocybin, MDMA, ketamine), moving them from scattered pilot projects toward an organized national program. That creates predictable funding streams, training expectations, and data collection standards — all of which can accelerate evidence generation, clinical adoption, and regulatory engagement, while concentrating technical capacity at selected sites.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new statutory section directing the VA to pick at least five medical facilities to operate as "innovative therapies centers of excellence." Designation turns on competitive proposals evaluated by a specialized peer review panel; once designated and funded, centers must run coordinated clinical, research, and education programs. The statute conditions actual establishment on appropriations but requires the Secretary and Under Secretary to pursue geographically distributed locations and national coordination.
Designation requires more than a promise to research novel drugs: a facility must demonstrate or feasibly develop formal affiliations with an accredited medical school (for resident education in innovative therapies), an accredited psychiatry school, and an accredited school of social work. Centers must also recruit research talent, set up veteran-and-expert advisory committees, evaluate their own activities, and build mechanisms — including a national data repository and regional consortia — to extend access and standardize care across the VA system.The bill creates a peer review panel of experts in "innovative therapies" to rank facility proposals by scientific and clinical merit.
Panel members serve short terms (two years, with staggered initial appointments) and the statute expressly exempts the panel from chapter 10 of title 5, which limits certain procedural constraints on the panel's operation. The Under Secretary must deliver an initial report two years after enactment and then annual reports to the Veterans’ Affairs Committees summarizing activities, findings, and recommendations.
Funding is addressed via an explicit authorization of $30 million per fiscal year for research and education and grants the Under Secretary discretion to reallocate other VA medical services and research funds to the centers.
The Five Things You Need to Know
The bill requires the Secretary to designate at least five VA medical facilities as innovative therapies centers of excellence, with geographic distribution required.
It authorizes $30,000,000 per fiscal year for research and education at the centers and permits the Under Secretary to reallocate amounts from VA medical services and medical and prosthetics research accounts.
Designation depends on a competitive proposal judged by a new peer review panel of 'innovative therapies' experts; panel members serve up to two years with staggered initial terms and the panel is exempted from chapter 10 of title 5.
Each designated center must have or reasonably anticipate affiliations with an accredited medical school (for resident training in innovative therapies), an accredited school of psychiatry, and an accredited school of social work, plus advisory committees including veterans.
The statute defines covered conditions (e.g.
PTSD, chronic pain, depression, substance use disorder, Parkinson’s, anxiety, bipolar disorder) and lists specific 'innovative therapies' including MDMA, psilocybin, ketamine, ibogaine, and 5-MeO-DMT, with the Under Secretary able to add more.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishes and requires designation of centers
Subsection (a) directs the Secretary, on recommendation from the Under Secretary for Health, to designate not fewer than five VA medical facilities as the locations for innovative therapies centers of excellence and to establish and operate such centers subject to available appropriations. Practically, this creates a statutory floor (five centers) but ties operations to Congress providing funds; designation without funding remains possible but establishment depends on appropriations.
Geographic distribution requirement
Subsection (b) requires that designations ensure appropriate geographic distribution. The bill leaves 'appropriate' undefined, so the VA retains latitude to balance regional access against proximity to academic partners; however, this language creates an explicit obligation to avoid concentrating centers in a single region.
Designation criteria and institutional requirements
Subsection (c) lays out the threshold criteria facilities must meet in their competitive proposals: formal or reasonably anticipated affiliations with accredited medical schools, psychiatry schools, and social work schools; capacity to recruit inventive scientists; veteran-inclusive advisory committees; evaluation capability; integrated national coordination; consortium-building to include non-center VA facilities; and development of a national data repository. These are operational expectations that will shape budgets, hiring, IT infrastructure, and academic agreements at candidate facilities.
Peer review panel to judge proposals
Subsection (d) requires the Under Secretary to establish a panel of experts in 'innovative therapies' to assess proposals and report on scientific and clinical merit. Membership terms are short (two-year standard, with staggered initial appointments). The subsection explicitly removes the panel from chapter 10 of title 5, which limits application of certain administrative procedural requirements — a detail that affects how the panel operates, its transparency obligations, and conflicts-of-interest handling.
Reporting and funding
Subsection (e) mandates an initial report two years after enactment and annual reports thereafter to the Veterans’ Affairs Committees, covering activities, key findings, and recommendations. Subsection (f) authorizes $30 million per year for research and education and directs the Under Secretary to allocate other VA medical services and research funds as deemed appropriate. That combination creates a baseline funding expectation while allowing internal VA transfers to supplement centers.
Definitions of covered conditions and innovative therapies
Subsection (g) defines 'covered condition' to include anxiety, bipolar disorder, chronic pain, depression, Parkinson’s disease, PTSD, and substance use disorder, with the Under Secretary allowed to add others. It also lists specific 'innovative therapies' — MDMA, 5-MeO-DMT, ibogaine, ketamine, and psilocybin — and allows the Under Secretary to designate additional therapies. These definitions set the clinical scope and explicitly bring several controlled or experimental agents into the program's remit.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with listed conditions (e.g., PTSD, chronic pain, substance use disorders): The statute creates dedicated centers with training, research-driven protocols, and a pathway to access therapies that are not yet widespread in standard VA clinics.
- VA researchers and affiliated academic investigators: Designation brings concentrated research funding, access to a national data repository, and formalized consortium opportunities that can accelerate clinical trials and publication avenues.
- Academic medical centers and residency programs (psychiatry, social work): Affiliated schools gain structured training opportunities for residents and students in emerging therapeutic modalities, strengthening recruitment and program portfolios.
- Biopharmaceutical and device developers working on specified therapies: Centralized centers and coordinated data collection create clearer engagement points for partnerships, clinical studies, and potential evidence development needed for regulatory approval.
- Mental health clinicians within the VA system: The bill funds education and creates clinical pathways and guidelines via centers, increasing provider competence and institutional support for administering complex treatments.
Who Bears the Cost
- VA medical centers seeking designation: They must invest in affiliate agreements, hiring research-capable staff, IT for repositories, training programs, and advisory committee support — costs that may exceed allocated center funds initially.
- The Department of Veterans Affairs central budget and medical services accounts: While $30 million is authorized annually, the Under Secretary may reallocate existing medical services and research funds to support centers, potentially diverting resources from other VA priorities.
- Under Secretary for Health and VA administrative staff: Implementing the peer review panel, developing reporting systems, maintaining the repository, and managing consortia will demand administrative capacity and program oversight.
- State regulatory and law enforcement agencies (indirectly): Because many named therapies are controlled or restricted substances, states and localities may face increased requests for licensing, oversight, or coordination around VA-provided services.
- Non-VA community providers: Concentration of specialized expertise and data in VA centers may centralize referrals and research access within the VA, changing competitive dynamics for private clinics seeking to offer similar therapies to veterans.
Key Issues
The Core Tension
The central dilemma is between accelerating veteran access to promising but experimental therapies through concentrated, well-funded centers and ensuring rigorous safety, regulatory compliance, transparent governance, and equitable access — a clash between speed and scale on one side and oversight, funding sufficiency, and patient protections on the other.
The bill folds a set of tightly regulated, sometimes illicit or controlled substances into VA care and research without addressing several operational and regulatory chokepoints. Conducting clinical programs with agents such as MDMA, psilocybin, and ibogaine requires controlled-substance authorizations, INDs or similar FDA oversight, and DEA scheduling coordination; the statute does not map those processes or provide supplemental authorities to streamline federal regulatory approvals.
That gap could delay meaningful program rollouts even if appropriations are available.
The financing structure creates a tension between the authorized $30 million and the broader resource needs for facilities to meet affiliation, staffing, and IT requirements. The Under Secretary’s discretion to reallocate funds from the VA medical services and research accounts provides flexibility but risks shifting money away from existing services.
The peer review panel’s exemption from chapter 10 of title 5 also raises governance questions: without typical procedural constraints, the panel may operate with fewer transparency and conflict-of-interest safeguards, complicating external oversight and stakeholder trust. Finally, the bill sets several qualitative obligations ("appropriate geographic distribution," "capability to conduct evaluations") without quantitative metrics or timelines, leaving critical implementation trade-offs to agency rulemaking and internal priorities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.